Data size not at all unusual for a Phase 2a trial. As Gary mentioned again in today's webinar - the Ph3 trial will probably looking towards 300 participants. If you look at the slide in today's presentation - the competition that did a phase 3 trial had much lower numbers than our intended Ph3 will, and two of the three barely had double the number of our Ph2!
- Forums
- ASX - By Stock
- Ann: Presentation: Phase 2 study of SNT-5505 in myelofibrosis
SNT
syntara limited
Add to My Watchlist
3.45%
!
5.6¢

Data size not at all unusual for a Phase 2a trial. As Gary...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
5.6¢ |
Change
-0.002(3.45%) |
Mkt cap ! $90.99M |
Open | High | Low | Value | Volume |
5.8¢ | 5.9¢ | 5.6¢ | $157.1K | 2.771M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 106128 | 5.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.6¢ | 241692 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 106128 | 0.055 |
3 | 154103 | 0.054 |
5 | 466292 | 0.053 |
3 | 172230 | 0.052 |
3 | 372100 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.056 | 239705 | 4 |
0.057 | 548081 | 4 |
0.058 | 310398 | 2 |
0.059 | 16070 | 1 |
0.060 | 256924 | 4 |
Last trade - 15.10pm 18/06/2025 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online